A true passion for health and prevention

A true passion for health and prevention

As one of the oldest pharmaceutical companies in the region, Galenika marked its 79th anniversary this year. The tradition that Galenika takes pride in is something that consumers greatly appreciate, alongside the proven quality of its pharmaceutical products, as demonstrated by research results. On the other hand, this tradition stands alongside Galenika’s focus on the future and the modernization of its production portfolio, all for the benefit of patients. After all, to remain relevant in the future, you must start planning for that future well in advance.

This year has been particularly significant, not only because of the anniversary but also due to the company’s notable regional expansion and portfolio growth. With double-digit growth expected in 2025, Galenika continues to strengthen its position in the pharmaceutical industry.

Karlos Pulja, Executive Director of Sales and Marketing at Galenika, told us:

“The greatest achievement this year is that we have continued the process of regional expansion and started operations in two new EU countries, Slovakia and the Czech Republic. Since the beginning of 2024, we have launched 50 products in Serbia and have had noticeable expansion in the regional and EU markets, where we launched 230 products.”

Recognition for Contributions to Health and Prevention

Another testament to Galenika’s corporate planning and results being on the right track is the award the company recently received at the “World in 2025” conference for outstanding contributions to health and prevention.

The expansion of Galenika’s product range strengthens the company’s market position and, most importantly, offers consumers and patients a wide array of modern, effective, top-quality pharmaceutical products that contribute to health. This year, Galenika has also been involved in numerous important projects aimed at raising awareness about the importance of health and prevention. From the “Galenika Pink October” campaign and donation to the multi-award-winning online platform “Healthy Twenties,” Galenika’s initiatives show how important prevention is on the company’s agenda.

Last year, Galenika began new investment cycles worth 35 million euros for the 2023–25 period, focusing on further expanding state-of-the-art production capacities and environmental protection. Galenika’s prescription drug portfolio is very strong, accounting for almost two-thirds (65%) of the company’s total portfolio. In the over-the-counter (OTC) segment, the company focuses on growth, offering consumers modern therapies for their contemporary needs. Dermocosmetics is one of the areas that Galenika has identified as particularly important today, along with the dietary products segment.

“Last year, Galenika acquired Lifemedic in Serbia and began an exclusive distribution partnership with the Italian manufacturer Pharmalife Research, a reliable producer of pediatric medicines and dietary supplements. In the meantime, not only have we integrated the new company, team, and portfolio into Galenika, but we have also increased sales in the Serbian market by 10%. This is one of the things that proves the Lifemedic portfolio has already integrated well into our portfolio,” highlighted Karlos Pulja of Galenika.

The Importance of Portfolio Expansion for Consumers

This year, Galenika continued its strategic portfolio expansion through a partnership and an exclusive agreement with one of Spain’s leading manufacturers of high-end dermatological brands, present in 85 markets worldwide. In this way, Galenika took on the exclusive distribution of Cantabria Labs brands for the markets of Serbia, Montenegro, and North Macedonia, ensuring not only portfolio expansion but also the highest quality standards and products that are leaders in their categories across Europe. The company achieved excellent results in the initial months following this launch, which confirms the business decision and market assessment.

Additionally, Galenika has just signed another international agreement with the Austrian company CromaPharma, which offers top-quality hyaluronic acid-based products for skincare and is present in global markets. With this business move, Galenika announces the distribution of seven new products from the aesthetic medicine segment for the Serbian and Bosnian markets.

Karlos Pulja, Executive Director of Sales and Marketing at Galenika, explains:
“New business partnerships increase our capacity and competitiveness and strengthen our presence in EU countries. They strategically enrich Galenika’s portfolio with modern, effective, high-quality pharmaceutical products that consumers, pharmacists, and doctors clearly recognize and appreciate. These partnerships also contribute to our contemporary vision and mission for health and prevention.”

Leadership and Company Plans

Being a leader in the pharmaceutical industry requires expertise, constant investment in technology, digitalization, and further development of production capacities, along with the expansion of business presence in international markets. After initially opening EU offices in Hungary, Croatia, and Slovenia, this year, Galenika opened new markets – Portugal, the Czech Republic, and Slovakia.

Regarding the company’s future plans and what is important in the market, Karlos Pulja, Executive Director of Sales and Marketing at Galenika, stated:

“We are planning dynamic growth in new EU markets and expanding our prescription drug portfolio in the Balkans. We are also preparing the company for the launch of peptides, which is a significant milestone for us, the market, the Brazilian NC Group to which Galenika belongs, and the industry itself.”

Direct Interaction with People Still Makes a Difference

Speaking about the human aspect of the pharmaceutical industry, our interviewee emphasized:

“Internal and external communication and the relationships we build are very important. Quality, innovation, investment, and advanced technology – all of these are crucial. But direct interaction with people still makes the difference and will continue to do so in the future. Our employees and teams have a true passion for health and prevention. That’s what makes Galenika stand out.”

The interview was published on the Mondo.rs portal on December 16, 2024.
https://mondo.rs/Info/Drustvo/a2013821/istinska-strast-prema-zdravlju-i-prevenciji.html


Share:
824 PREGLEDA